Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019047941) AMANITIN ANTIBODY CONJUGATE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/047941 International Application No.: PCT/CN2018/104712
Publication Date: 14.03.2019 International Filing Date: 08.09.2018
IPC:
A61K 47/00 (2006.01) ,A61K 39/395 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
四川百利药业有限责任公司 SICHUAN BAILI PHARM CO. LTD [CN/CN]; 中国四川省成都市 温江区成都海峡两岸科技产业开发园区王菁 WANG, Jing Cross-Strait Science and Technology Industrial Development Zone, Wen Jiang Chengdu, Sichuan 611130, CN
Inventors:
朱义 ZHU, Yi; CN
李杰 LI, Jie; CN
万维李 WAN, Weili; CN
余永国 YU, Yongguo; CN
卓识 ZHUO, Shi; CN
Priority Data:
201710804207.808.09.2017CN
Title (EN) AMANITIN ANTIBODY CONJUGATE
(FR) CONJUGUÉ D'ANTICORPS À BASE D'AMANITINE
(ZH) 鹅膏毒肽类抗体偶联物
Abstract:
(EN) A bicyclic octapeptide derivative is conjugated to a corresponding target-binding group by a special chemical structure. The structure of the derivative is stable in blood plasma and decomposes into a drug as an active ingredient in a specific biological environment, thereby maximizing killing effect on target cells and minimizing toxic side effects on non-target cells. The derivative can be used in the treatment of various malignant tumors.
(FR) Un dérivé octapeptidique bicyclique est conjugué à un groupe de liaison à la cible correspondant par une structure chimique spéciale. La structure du dérivé est stable dans le plasma sanguin et se décompose en un médicament en tant que principe actif dans un environnement biologique spécifique, ce qui permet de maximiser l'effet destructeur sur les cellules cibles et de minimiser les effets secondaires toxiques sur les cellules non cibles. Le dérivé peut être utilisé dans le traitement de diverses tumeurs malignes.
(ZH) 二环八肽类衍生物以特殊的化学结构与相应的靶结合基团偶联,其结构在血浆中稳定而在特定的生物环境中裂解成为活性成份的药物,以达到对靶细胞杀伤性的最大化和对非靶细胞毒害副作用的最小化,可用于多种恶性肿瘤的治疗。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)